Moving right along

The Investor Newsletter for August 2016 contained a particularly intriguing comment;
"We think Imugene will be in the foreground of some exciting combinations in the near future".

If anyone wondered what that might mean, we didn't have long to find out.

Today's release of Review of Operations and Activities contains information on new exploratory work on HER-Vaxx in combination with checkpoint inhibitors. This is an exciting development.

There is an existing clinical trial which may throw some light on the reasoning behind the combination of HER-Vaxx and a checkpoint inhibitor in HER-2 positive gastric cancer. In the Panacea trial, investigators are examining the combination of Keytruda and Herceptin and whether a checkpoint inhibitor can reverse Herceptin resistance in HER-2 positive breast cancer and improve clinical outcomes.

Concurrently funding pre-clinical work in combination therapies along with the HER-Vaxx Phase 1b/2 clinical trial, totally suggests that Imugene is both confident and excited about future developments.